AVTXAvalo Therapeutics, Inc.
$13.43-0.37% 1Y
$13.43
$12.7452 weeks$22.87
AVTX in its own filings
AVTX's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
362
Events found in the filings · across 1,213 filings · the record starts in 2014
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 10-Q
- Record starts
- Jan 16, 2014
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Delisting notice / listing-rule failure13 occurrences
- 2024-05-23
- Security removed from listing or deregistered3 occurrences · usually a matured note or preferred class, not the common shares
- 2018-10-17
- SEC comment-letter activity52 occurrences
- 2026-01-15
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates.Earnings release · press release
- Jun 23, 2026On June 23, 2026, the board of directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Ron Philip to the Board, effective June 23, 2026.Director or officer change · Form 8-K
- Jun 16, 2026On June 16, 2026, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders.Other event · Form 8-K
- Jun 12, 2026On June 12, 2026 (the “Effective Date”), the Company entered into amendments to employment agreements with Garry A. Neil, M.D., the Company’s Chief Executive Officer, Christopher Sullivan, the Company’s Chief Financial Officer, Mittie Doyle, M.D., FACR, the Company’s Chief Medical Officer and Taylor Boyd, Chief …Unregistered sale of equity · Form 8-K
- Jun 8, 2026Equity Plan Amendments As noted in.Director or officer change · Form 8-K
- May 13, 2026Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates.Earnings release · press release
- May 7, 2026On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the …Material agreement entered · Form 8-K
- May 5, 2026On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from its Phase 2 LOTUS trial evaluating the efficacy, safety and tolerability of abdakibart in patients with moderate to severe hidradenitis suppurativa.Other event · Form 8-K
- Apr 28, 2026On April 26, 2026 (the “Effective Date”), Avalo Therapeutics, Inc. (the “Company”) entered into a Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization (the “Milestone Buyout and Amendment Agreement”)Material agreement entered · Form 8-K
- Mar 27, 2026On March 23, 2026, Dr. Jonathan Goldman and Mitchell Chan, members of the board of directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”), each notified the Company of his decision to not stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”)Director or officer change · Form 8-K
- Mar 23, 2026Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates.Earnings release · press release
- Jan 12, 2026The Company has posted on its website an updated investor presentation (the “Investor Presentation”). The Investor Presentation will be used from time to time in meetings with investors.Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…